Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

× No keyword cloud information.

129 in total

Review 1. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.

Authors: Jing Ai; Ramon V Tiu
Journal: Ther Adv Hematol Date: 2014-08

2. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

Authors: Naoto Takahashi; Chiaki Nakaseko; Yukio Kobayashi; Koichi Miyamura; Chiho Ono; Yuichiro Koide; Yosuke Fujii; Kazunori Ohnishi
Journal: Int J Hematol Date: 2017-04-13 Impact factor: 2.490

3. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.

Authors: Sailaja Kagita; Srihari Uppalapati; Sangeeta Jiwatani; Vijay Gandhi Linga; Sadasivudu Gundeti; Narayana Nagesh; Raghunadharao Digumarti
Journal: Tumour Biol Date: 2014-04-26

4. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Authors: Hagop Kantarjian; Jorge Cortes
Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544

5. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors: Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal: Am J Hematol Date: 2011-09 Impact factor: 10.047

Review 6. Mechanisms of drug resistance in kinases.

Authors: Rina Barouch-Bentov; Karsten Sauer
Journal: Expert Opin Investig Drugs Date: 2011-02 Impact factor: 6.206

7. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Authors: Qiangui Bu; Lijing Cui; Juan Li; Xin Du; Waiyi Zou; Ke Ding; Jingxuan Pan
Journal: Cancer Biol Ther Date: 2014-04-23 Impact factor: 4.742

8. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Authors: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Hagop Kantarjian
Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544

9. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Authors: Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger
Journal: Blood Date: 2012-12-05 Impact factor: 22.113

10. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Authors: Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus
Journal: Blood Date: 2009-09-24 Impact factor: 22.113